Aspen agrees to buy GSK drugs for $967 million
JOHANNESBURG, Sept 30
JOHANNESBURG, Sept 30 (Reuters) - South Africa's Aspen Pharmacare said on Monday it had agreed to a price of 600 million pounds ($967 million) to buy thrombosis drugs and a factory from shareholder GlaxoSmithKline.
Aspen and Britain's Glaxo first announced the deal in June.
Trending On Reuters
Strategies for making the most of your donations - from how to grow the money you plan to give to how to withdraw it with minimal tax implications. Video